Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Spiral Therapeutics Announces First Closing Of A Series A Financing And Begins Phase 1 Trial Of New Hearing Loss Drug
Venture Capital

Spiral Therapeutics Announces First Closing Of A Series A Financing And Begins Phase 1 Trial Of New Hearing Loss Drug

by vcaonline.com posted 3weeks ago 261 views
Spiral Therapeutics Announces First Closing of a Series A Financing and Begins Phase 1 Trial of New Hearing Loss Drug SAN FRANCISCO, December 18, 2018-- Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies targeting inner ear disorders, today announced the initiation of its Phase 1 clinical trial of LPT99, the company's lead investigational drug candidate targeting prevention and treatment of hearing loss.

In this article